Meihua International Faces Nasdaq Minimum Bid Price Non-Compliance

TL;DR

Meihua International is at risk of being delisted from Nasdaq due to low stock price.

AI Summary

On April 2, 2024, Meihua International Medical Technologies Co., Ltd. received a notification from the Nasdaq Stock Market stating that the company is no longer in compliance with the minimum bid price requirement. The company must regain compliance within a specified period to avoid delisting.

Why It Matters

Failure to meet Nasdaq's minimum bid price requirement could lead to the company's stock being delisted, impacting its liquidity and investor confidence.

Risk Assessment

Risk Level: medium — The company is non-compliant with Nasdaq's minimum bid price rule, which could lead to delisting if not rectified.

Key Players & Entities

• Meihua International Medical Technologies Co., Ltd. (company) — The company filing the report and receiving the notification.
• Nasdaq Stock Market, LLC (company) — The exchange that issued the non-compliance notification.
• April 2, 2024 (date) — The date the company received the notification.

FAQ

Key Financial Figures

• $1.00 — squo;s ordinary shares closed below the $1.00 per share minimum bid price required fo
• $5,000 — mpany would be required to pay Nasdaq a $5,000 application fee to transfer to the Nasd

Filing Documents

• ea0203243-6k_meihuainter.htm (6-K) — 14KB
• 0001213900-24-029880.txt ( ) — 15KB

Forward-Looking Statements

Forward-Looking Statements This press release contains forward-looking concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking Company’s ability to achieve its goals and strategies, financial conditions and results of operations, product and service demand and acceptance, reputation and brand, the impact of competition and pricing, changes in technology, government regulations, fluctuations in general economic and business conditions in China, the Company’s ability to take such action as may be required to regain compliance with the Nasdaq listing requirements, and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the U.S. Securities and Exchange Commission (“SEC”). For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this Current Report on Form 6-K. Additional factors are discussed in the Company’s filings with the SEC, including under the section entitled “Risk

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Meihua International Medical Technologies Co., Ltd. Dated: April 3, 2024 By: /s/ Xin Wang Name: Xin Wang Title: Chief Executive Officer (Principal Executive Officer) 2

View Full Filing

View this 6-K filing on SEC EDGAR